Regeneron Archives - DelveInsight

Regeneron

Pharma-news
Regeneron’s I-O Drug; Gene Therapy for Parkinson’s Disease; Yumanity and Merck Inks $...

Regeneron recognizes new combos to boost I-O drug Libtayo's cancer responsePD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patients combat several types of ...


Pharma News
JNJ-6372 nabs FDA nods, Solid tumors treatment, Kevzara for COVID-19

The U.S. FDA has granted Janssen Pharmaceutical’s drug JNJ-6372, a Breakthrough Therapy designation for the treatment of metastatic non-small cell lung cancer (NSCLC) The drug has been re...


Coronavirus (COVID- 19)
The epidemic now has a name: COVID-19

Amid the breakout in Wuhan, China, the novel coronavirus has managed to invade the other countries across the globe. Till now, almost 25 countries including several Asian, northern American, Aust...


World Pharma News
EU approval for Libtayo and Dovato; Boehringer expands NASH pipeline

EU approves the use of Libtayo for cutaneous squamous cell carcinomaThe National Institute for Health and Care Excellence (NICE), in a move to make cancer drugs available to common man, has is...


NOTIZIA
Notizia

A Praluent boost for Sanofi, and RegeneronThe U.S. FDA has given its nod to Praluent (alirocumab) to be used for reducing the risk of heart attack, stroke, and unstable angina requiring hospit...


Johnson & Johnson
Notizia

If dementia genes are found, drug discovery can be accelerated in brain disorders The overproduction of a protein called tau has been detected in the neuron degeneration that causes Alzheimer’s and...


Hot flashes
Notizia

TherapeuticsMD bags FDA approval for hormone therapy The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an oral treatment that contai...


transthyretin amyloidosis
Regeneron/Sanofi’s PD-1 drug candidate; Zika targeting drugs and vaccines developments; CMO of Ac...

Regeneron/Sanofi’s PD-1 drug candidate will be tested with ISA’s HPV immunotherapy Regeneron and Sanofi’s PD-1 candidate cemiplimab is paired with Dutch biotech ISA Pharma’s human papillomavirus (H...


transthyretin amyloidosis
Roche’s Phase 2 data; Celgene and Bluebird’s CAR-T therapy; Regeneron/Sanofi gets results; Allerg...

Positive Phase 2 data for Roche’s lymphoma ADC Roche’s antibody-drug conjugate for non-Hodgkin lymphoma polatuzumab has already received breakthrough designation from the USFDA and priority medici...


Novartis on AMD drug; Hospira recall of vials; Takeda wraps up; FDA bans imports

Novartis takes on Regeneron with AMD drug that needs fewer doses than Eylea Last year, U.S. sales of Regeneron’s drug to treat age-related macular degeneration (AMD) came in at $3.3 billion—68% of ...


Editor's Pick
Bone Metastasis Market: A Debilitating Consequence for Many Tumors

In advanced cancer patients, the most common site for the occurrence of metastasis is c...

Evaluating the Role of Digital Therapeutics as an Alternative to Conventional...

Depression is a mental condition characterized by prolonged series of poor moods, loss ...

Exploring the Market Potential of the Upcoming Therapies for the Myasthenia G...

Myasthenia Gravis is an autoimmune disease that causes muscle weakness and fatigue. It ...

Scrutinizing the West Syndrome Market Space from Growth Perspectives

West syndrome is a rare form of neurological disorder, an age-related specific Epilepti...

Recent Inclination of Pharma Companies, Emerging Pipeline Therapies Drive the...

Chronic diseases (CDs) pose a significant challenge to healthcare in the 21st century. ...

ASCO Conference 2021
ASCO Conference 2021

The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.